Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD
Shots:
- The Study 102 involves assessing of SRP-9001 vs PBO in 41 patients in a ratio (1:1) with DMD aged 4-7yrs.
- Results: @12wks. post treatment- the study met its 1EPs of micro-dystrophin protein expression- as measured by western blot. @48wks. increase in NSAA total score- however- the study did not achieve significance on the primary functional endpoint of improvement in NSAA total score @48wks. post-treatment
- The pre-specified analysis of patients aged 4-5yrs. showed improvement in NSAA total score (4.3 vs 1.9 points). No new safety signals identified for SRP-9001- reinforcing the favorable safety profile
Ref: GlobeNewswire | Image: The Business Journals
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com